---
title: "Tempus AI secures $200 million five-year commitment from AstraZeneca"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/305978953.md"
description: "Tempus AI has secured a $200 million, five-year spending commitment from AstraZeneca through a contract amendment effective January 1, 2027. The agreement extends their master services agreement until December 31, 2031, with AstraZeneca targeting annual spending of $40 million and a minimum of $32 million per year. If the aggregate commitment is not met, the term extends to 2032. AstraZeneca retains termination rights but must pay any shortfall against the $200 million total."
datetime: "2026-11-18T13:34:21.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/305978953.md)
  - [en](https://longbridge.com/en/news/305978953.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/305978953.md)
generator: "portal-rs"
---

# Tempus AI secures $200 million five-year commitment from AstraZeneca

-   Tempus AI signed a contract amendment with AstraZeneca on November 16, 2026, securing a $200 million, five-year spending commitment. \* The renewal takes effect January 1, 2027, extending the master services agreement through December 31, 2031. \* AstraZeneca targets annual spending of $40 million across products and services, with a $32 million minimum each calendar year. \* An unmet aggregate commitment would extend the renewal through December 31, 2032, to address the shortfall. \* AstraZeneca retains termination rights but must pay any shortfall against its $200 million commitment if it terminates for convenience. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempus AI Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-466240), on November 18, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [AZN.US](https://longbridge.com/en/quote/AZN.US.md)
- [TEM.US](https://longbridge.com/en/quote/TEM.US.md)
- [TEMC.US](https://longbridge.com/en/quote/TEMC.US.md)
- [TEMT.US](https://longbridge.com/en/quote/TEMT.US.md)
- [AZN.UK](https://longbridge.com/en/quote/AZN.UK.md)

## Related News & Research

- [Tempus Ai - Co And Astrazeneca AB Enter Fifth Amendment To Master Services Agreement On Nov 16](https://longbridge.com/en/news/305980109.md)
- [AstraZeneca Extends Tempus AI Partnership with $200 Million Commitment as Analyst Weighs Multiples](https://longbridge.com/en/news/306157216.md)
- [Tempus AI to Present Breast Cancer Treatment Prediction Study at 2026 SABCS](https://longbridge.com/en/news/306119134.md)
- [AstraZeneca's sonesitatug vedotin gets FDA priority review for advanced gastric cancers](https://longbridge.com/en/news/306076537.md)
- [AstraZeneca (AZN) Wins FDA Approval for IMFINZI Bladder Cancer Regimen](https://longbridge.com/en/news/305514953.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**